positive results of us physician market resear

ACRUX REPORTS POSITIVE RESULTS OF US PHYSICIAN
MARKET RESEARCH ON TESTOSTERONE MD-LOTION®

�� 91% of physicians surveyed in the US rated Testosterone MD-Lotion
as very good or excellent in being able to improve the patient
experience, compared with existing gel treatments
�� 87% of physicians said they would offer Testosterone MD-Lotion to
their existing gel patients
Melbourne, 31 July 2008: Acrux (ASX: ACR), today announced the positive
results of a market research study on the attitudes of physicians towards
Testosterone MD-Lotion, its novel treatment for hypogonadism currently in a
Phase 3 trial.
The study was conducted in two phases, involving the main prescribing groups
for testosterone therapy. The first phase was qualitative and involved 14 indepth
interviews with doctors in the US and Australia. The second phase,
conducted solely in the US with a total of 136 doctors, was a quantitative survey
and involved 51 Endocrinologists, 53 Urologists, and 32 Primary Care Physicians.
The objective of the study was to confirm the decision-making process of
prescribers when diagnosing and choosing a treatment for patients with
hypogonadism, and to gather their perceptions of Testosterone MD-Lotion
against existing treatments. The results strongly reinforce the positive findings
from Acrux’s previous market research with 81 hypogonadal men, which were
announced in February 2008.
After being introduced to Testosterone MD-Lotion, 91% of all physicians surveyed
rated the product very good or excellent in being able to improve the overall
patient experience, compared with existing gel treatments. This positive
endorsement of the product complements the results obtained from the previous
study conducted in patients, which showed that 77% of those who trialled
Testosterone MD-Lotion for 4 days rated it easier to apply than their existing gel.

When asked about their intention to prescribe the product, 87% of all physicians
said they would offer Testosterone MD-Lotion to their existing gel patients and
62% would offer it to their new patients. This high intent to use amongst
doctors, coupled with the previous study finding that 62% of patients would
switch to Testosterone MD-Lotion if their doctor recommended it, provides
further evidence of the compelling proposition of Testosterone MD-Lotion.
Commenting on the results, Acrux CEO Richard Treagus said “This positive
endorsement of Testosterone MD-Lotion by a cross section of US physicians
complements the strong patient preference already shown by our previous
research. This provides the clearest indicator yet of the potential for the Acrux
product to capture a significant share of the US$900 million testosterone therapy
market”.